HER2 antibody-drug conjugate controls growth of breast cancer brain metastases in hematogenous xenograft models, with heterogeneous blood–tumor barrier penetration unlinked to a passive marker

BACKGROUND: Brain metastases of HER2+ breast cancer persist as a clinical challenge. Many therapeutics directed at human epidermal growth factor receptor 2 (HER2) are antibodies or antibody-drug conjugates (ADCs), and their permeability through the blood–tumor barrier (BTB) is poorly understood. We...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Autores principales: Gril, Brunilde, Wei, Debbie, Zimmer, Alexandra S, Robinson, Christina, Khan, Imran, Difilippantonio, Simone, Overstreet, Michael G, Steeg, Patricia S
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2020
Materias:
Basic and Translational Investigations
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7690367/
https://ncbi.nlm.nih.gov/pubmed/32386414
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa118
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares